Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...
https://www.tipranks.com/news/the-fly/insulet-price-target-raised-to-300-from-270-at-btig Immutep (IMMP) announces positive clinical results from Cohort B of the ...
Hosted on MSN20d
Immutep Ltd Reveals Key LAG-3 Binding DiscoveryImmutep Ltd (AU:IMM) has released an update. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart ...
SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology ...
Immutep (IMMP) announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer, 1L NSCLC. “The receipt of ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback